文献速递消化内镜消化道出血

直接口服抗凝药与内镜黏膜下剥离术后迟发出血的药代动力学关联

Association of direct oral anticoagulant and delayed bleeding with pharmacokinetics after endoscopic submucosal dissection.
PubMed 文献 · Gastrointest Endosc · 2023-12-01

本研究在日本21家机构前瞻性评估2018年4月至2022年5月服用直接口服抗凝药(DOAC)患者内镜黏膜下剥离术(ESD)后出血发生率及其与药代动力学参数的关联。ESD后出血发生率为12.8%(109例中14例;95%CI 7.2-20.6)。多因素分析显示,较高年龄(OR 1.192;95%CI 1.020-1.392;P=.027)和谷浓度与Tmax时FXa活性分析的高抗凝能力(OR 6.056;95%CI 1.094-33.529;P=.039)是ESD后出血的危险因素。

要点

  • 服用DOAC患者ESD后出血发生率为12.8%(109例中14例;95%CI 7.2-20.6)。
  • 较高年龄是ESD后出血的危险因素(OR 1.192;95%CI 1.020-1.392;P=.027)。
  • 谷浓度与Tmax时FXa活性分析的高抗凝能力是ESD后出血的危险因素(OR 6.056;95%CI 1.094-33.529;P=.039)。

核心结论

  • 服用DOAC患者ESD后出血发生率较高,尤其在高龄和DOAC抗凝效应强的患者中。
  • 测量DOAC药代动力学参数可能有助于识别ESD后出血风险较高的患者。

研究设计与样本

  • 前瞻性评估2018年4月至2022年5月在日本21家机构服用DOAC患者ESD后出血发生率及其与药代动力学因素的关联。

主要发现

  • ESD后出血发生率为12.8%(109例中14例;95%CI 7.2-20.6)。
  • DOAC血浆浓度及谷浓度与Tmax时血浆水平/剂量比个体间差异大,但血浆浓度与FXa活性观察到显著相关性(阿哌沙班:相关系数-0.893;P<.001)。
  • 多因素分析显示ESD后出血危险因素为较高年龄(OR 1.192;95%CI 1.020-1.392;P=.027)和谷浓度与Tmax时FXa活性分析的高抗凝能力(OR 6.056;95%CI 1.094-33.529;P=.039)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Pharmacokinetic parameters, such as drug plasma level at trough, time to maximum plasma concentration (Tmax), and coagulation factor Xa (FXa) activity generally predict factors for the anticoagulant effects of direct oral anticoagulants (DOACs). Although GI bleeding is a major adverse event after endoscopic submucosal dissection (ESD), little is known about the association between post-ESD bleeding in patients taking DOACs and the pharmacologic parameters. This study aimed to evaluate pharmacologic risk factors for post-ESD bleeding in patients taking DOACs. METHODS: We prospectively evaluated the incidence of post-ESD bleeding in patients taking DOACs between April 2018 and May 2022 at 21 Japanese institutions and investigated the association with post-ESD bleeding and pharmacologic factors, including plasma concentration and FXa activity at trough and Tmax. RESULTS: The incidence of post-ESD bleeding was 12.8% (14 of 109; 95% confidence interval [CI], 7.2-20.6). Although plasma DOAC concentration and plasma level/dose ratio at trough and Tmax varied widely among individuals, a significant correlation with plasma concentration and FXa activity was observed (apixaban: correlation coefficient, -0.893; P < .001). On multivariate analysis, risk factors for post-ESD bleeding in patients taking DOACs were higher age (odds ratio [OR], 1.192; 95% CI, 1.020-1.392; P = .027) and high anticoagulant ability analyzed by FXa activity at trough and Tmax (OR, 6.056; 95% CI, 1.094-33.529; P = .039). CONCLUSIONS: The incidence of post-ESD bleeding in patients taking DOACs was high, especially in older patients and with high anticoagulant effects of DOACs. Measurement of pharmacokinetic parameters of DOACs may be useful in identifying patients at higher risk of post-ESD bleeding.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Murata M, Sugimoto M, Ueshima S, et al. Association of direct oral anticoagulant and delayed bleeding with pharmacokinetics after endoscopic submucosal dissection. Gastrointest Endosc. 2023. PMID: 38042206. doi:10.1016/j.gie.2023.11.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。